Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 19/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.86 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.86 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cp-866087 SCHEMBL14161503 | 0.92 | OPRM1 (1.00) | OPRM1KCNH2OPRD1OPRK1 | |
| Cp-866087 SCHEMBL16292952 | 0.92 | OPRM1 (1.00) | OPRM1KCNH2OPRD1OPRK1 | |
| Cp-866087 SCHEMBL4697312 | 0.92 | OPRM1 (1.00) | OPRM1KCNH2OPRD1OPRK1 | |
| Cp-866087 SCHEMBL4700040 | 0.91 | OPRM1 (0.98) | OPRM1KCNH2OPRD1OPRK1 | |
| Cp-866087 SCHEMBL18091510 | 0.91 | OPRM1 (0.98) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL4698666 | 0.87 | OPRM1 (0.66) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL4698114 | 0.86 | OPRM1 (0.88) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL4702514 | 0.86 | OPRM1 (0.84) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL4700444 | 0.85 | OPRM1 (0.85) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL4699391 | 0.85 | OPRM1 (0.76) | OPRM1KCNH2OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7049335-B2 | 3-azabicyclo[3.1.0]hexane derivatives | PFIZER INC. (US) | 2006-05-23 | — | — | US | claimed |
| EP-1440059-B1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070054950-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | PFIZER INC. | 2007-03-08 | — | — | US | disclosed |
| US-7049335-B2 | 3-azabicyclo[3.1.0]hexane derivatives | PFIZER INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20030087898-A1 | 3-azabicyclo[3.1.0]hexane derivatives | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087898-A1 | 3-azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885KCNH2 542/4885OPRD1 1/4885 |
| US-20070054950-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885KCNH2 546/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.